Every material Form 8-K ANAPTYSBIO, INC has filed with the SEC since May 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AnaptysBio disclosed that the Court granted a joint stipulation setting the post-trial briefing schedule in its consolidated litigation with Tesaro and GlaxoSmithKline, following a trial held July 14-17, 2026. The filing contains no ruling on the merits, so the outcome of the dispute remains unresolved for shareholders.
Trial of the consolidated Tesaro litigation was held July 14-17, 2026.
The Court granted the parties' Joint Stipulation on July 28, 2026.
AnaptysBio's opening post-trial brief is due August 21, 2026, and post-trial argument is set for October 20, 2026.
AnaptysBio entered a 12-month sublease on June 15, 2026, leasing about 45,057 rentable square feet of its San Diego premises to First Tracks Biotherapeutics. The company stays responsible for its underlying master lease, and the sublease ends if its own tenancy ends, so the deal shifts occupancy costs to a subtenant without changing the company's core obligations.
Sublease covers about 45,057 rentable square feet at 10770 Wateridge Circle, San Diego, under a master lease with Wateridge Property Owner, LP.
First Tracks pays monthly rent equal to the Basic Rent and Additional Rent AnaptysBio owes under the master lease, due in advance on the first of each month.
Initial term is 12 months from June 15, 2026; First Tracks has a renewal option capped at April 4, 2028 and may terminate on three months' notice.
AnaptysBio has filed IRS Form 8937 and will post the same information on its website. The form covers tax treatment of the dividend stockholders received from the spin-off of First Tracks Biotherapeutics, and how the change in tax basis is determined. The filing is informational and the company urges stockholders to consult their own tax advisors.
AnaptysBio filed Form 8937 with the IRS, dated May 29, 2026.
The form describes the dividend stockholders received from the separation and spin-off of First Tracks Biotherapeutics, Inc.
The form explains how the dividend is treated for stockholders and how the change in tax basis is determined.
The company says the information is for informational purposes only and is not legal or tax advice.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ANAPTYSBIO, INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →